RemeGen Co Ltd
09995
Company Profile
Business description
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
Contact
58 Middle Beijing Road
Yantai Area of Shandong Pilot Free Trade Zone
Yantai Development Zone
Yantai
CHNT: +86 5353573511
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3,048
Stocks News & Analysis
stocks
Our view after CBA shares plunge
Steady profit, but rising risks and rich valuation give pause.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,862.50 | 3.90 | -0.04% |
| CAC 40 | 8,007.97 | 28.05 | 0.35% |
| DAX 40 | 24,136.81 | 181.88 | 0.76% |
| Dow JONES (US) | 49,693.20 | 67.36 | -0.14% |
| FTSE 100 | 10,325.35 | 60.03 | 0.58% |
| HKSE | 26,552.89 | 164.45 | 0.62% |
| NASDAQ | 26,402.34 | 314.14 | 1.20% |
| Nikkei 225 | 63,448.87 | 176.76 | 0.28% |
| NZX 50 Index | 13,020.65 | 42.41 | -0.32% |
| S&P 500 | 7,444.25 | 43.29 | 0.58% |
| S&P/ASX 200 | 8,617.70 | 3.00 | 0.03% |
| SSE Composite Index | 4,208.14 | 34.43 | -0.81% |